Neurobiology of opioid withdrawal: Role of the endothelin system

Life Sciences
Shaifali BhallaAnil Gulati

Abstract

Morphine and oxycodone are potent opioid analgesics most commonly used for the management of moderate to severe acute and chronic pain. Their clinical utility is limited by undesired side effects like analgesic tolerance, dependence, and withdrawal. We have previously demonstrated that endothelin-A (ETA) receptor antagonists potentiate opioid analgesia and eliminate analgesic tolerance. Mechanistically, G proteins and regulatory proteins such as β-arrestins have shown to play an important role in mediating opioid tolerance, dependence, and withdrawal. Recently, the involvement of central ET mechanisms in opioid withdrawal was investigated. ETA receptor antagonist was shown to block majority of the signs and symptoms associated with opioid withdrawal. This review focuses on ET as one of the potential novel strategies to manage the challenge of opioid withdrawal. An overview of additional players in this process (G proteins and β-arrestin2), and the possible therapeutic implications of these findings are presented.

References

Mar 1, 1992·Trends in Pharmacological Sciences·T SakuraiT Masaki
May 1, 1992·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S A SchugS Grond
Jan 1, 1991·Journal of Cardiovascular Pharmacology·M NiwaK Taniyama
Jan 1, 1991·Life Sciences·R B RaffaH I Jacoby
Jul 3, 1990·European Journal of Pharmacology·A Gulati, H N Bhargava
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M W MacCumberS H Snyder
Jul 1, 1990·The Journal of Clinical Investigation·M E LeeT Quertermous
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·K GotoT Masaki
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A GiaidJ M Polak
Dec 1, 1988·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·M YanagisawaT Masaki
Dec 1, 1988·Neuropharmacology·A Gulati, H N Bhargava
Mar 1, 1994·Trends in Neurosciences·G R UhlG Pasternak
Jan 1, 1995·Journal of Cardiovascular Pharmacology·A GulatiP R Saxena
Jul 1, 1997·Archives of General Psychiatry·R S DumanE J Nestler
Oct 6, 1997·Science·E J Nestler, G K Aghajanian
Jan 7, 1998·The Journal of Comparative Neurology·K KurokawaJ Ochi
May 22, 1998·Journal of Cardiovascular Pharmacology·H Yamada, K Kurokawa
May 29, 1998·Brain Research. Molecular Brain Research·S RoyH H Loh
Oct 31, 1998·Canadian Journal of Physiology and Pharmacology·H D Modanlou, K Beharry
Nov 11, 1998·Nature Medicine·P S ErikssonF H Gage
Apr 2, 1999·Trends in Pharmacological Sciences·B L Kieffer
Apr 5, 2000·The Journal of Biological Chemistry·T BremnesH Attramadal
Aug 5, 2000·Journal of Vascular Surgery·J BlebeaI S Zagon
Mar 22, 2001·Proceedings of the National Academy of Sciences of the United States of America·L CalzaR Levi-Montalcini
May 4, 2002·Nature Reviews. Neuroscience·Matti S Airaksinen, Mart Saarma
Oct 18, 2002·Peptides·Shaifali BhallaAnil Gulati
Aug 9, 2003·Neuropharmacology·Catherine M CahillTerence J Coderre
Mar 6, 2004·Neuromolecular Medicine·Carlos A Bolaños, Eric J Nestler
Sep 18, 2004·Trends in Neurosciences·Mark P MattsonBronwen Martin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.